Bausch & Lomb Incorporated
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Bausch & Lomb Incorporated sits in the top decile of US sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count).
Bausch & Lomb Incorporated: 174 sponsored US clinical trials, 3 recruiting.
Bausch & Lomb Incorporated sponsors 174 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 158 completed. 60 of these trials are in Phase 3-4 (later-stage) and 42 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Myopia, with 9 trials.
Top-decile sponsor footprint
Bausch & Lomb Incorporated ranks in the top decile of sponsors by registered trial count (#170 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
158 of 166 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
174 total, page 4 of 4
Corneal Endothelial Cell Density Changes In Healthy Subjects, When Administered ISV-403 for 5 Days
NCT01120418
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
NCT00441883
Evaluation of the Onset and Duration of Action of Bepotastine Besilate Ophthalmic Solution in Acute Allergic Conjunctivitis
NCT00424398
Zylet vs TobraDex in Blepharokeratoconjunctivitis
NCT00447577
Pediatric Zylet Safety and Efficacy Study
NCT00420628
Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis
NCT00423007
Systemic Pharmacokinetics of BOL-303224-A
NCT00407589
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
NCT00370747
A Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment (PVD)
NCT00347646
Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery
NCT00333918
Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment
NCT00348439
Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
NCT00560638
A Clinical Evaluation of the Next Generation Diagnostic Instrument (NGDI)
NCT00347594
Assessment of Intravitreous Injections of Vitrase for Inducing Posterior Vitreous Detachment
NCT00198471
A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
NCT00198523
A Study to Evaluate the Safety and Effectiveness of the Technols 217z Zyoptix System for Hyperopia
NCT00348205
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
NCT00198536
Evaluation of Vitrase as a Spreading Agent
NCT00198484
Evaluation of Vitrase as an Adjuvant to Increase Absorption and Dispersion of Other Injected Anesthetics
NCT00198549
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
NCT00198458
Hypersensitivity Reaction to Vitrase (Ovine Hyaluronidase)
NCT00198419
Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery
NCT00198445
Safety and Efficacy of Fluocinolone Acetonide Intravitreal Implants
NCT00407082
Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage
NCT00198510
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 26 |
| Phase 3 | 46 |
| Phase 4 | 14 |
Therapeutic Areas
What is open in the Bausch & Lomb Incorporated pipeline
3 recruiting of 174 indexed (2% open); 158 completed (91%).
Phase mix: 60 late (III/IV) vs 42 early (I/II) (balanced across stages).
Top condition: Myopia (9 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Bausch & Lomb Incorporated: open-pipeline peers nationwide
Peers matched on 174 registered trials and 2% open enrollment, not the therapeutic-area sidebar.
Bausch & Lomb Incorporated sits below the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 174 trials (± recruiting share)
- Albert Einstein College of Medicine · 175 trials · 11% recruiting
- UConn Health · 178 trials · 11% recruiting
- Tufts Medical Center · 169 trials · 11% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
Sponsors near 2% open enrollment (± trial volume)
- Medtronic Cardiac Rhythm and Heart Failure · 2% recruiting · 115 trials
- Eisai · 2% recruiting · 287 trials
- Lexicon Pharmaceuticals · 2% recruiting · 56 trials
- Alcon Research · 2% recruiting · 275 trials
Related
What to do with this Bausch & Lomb Incorporated page
174 registered trials is a research-attention snapshot, not an endorsement of Bausch & Lomb Incorporated or any single study.
- 3 of Bausch & Lomb Incorporated's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Myopia is the condition Bausch & Lomb Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Myopia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Bausch & Lomb Incorporated pipeline card: 174 registered trials from official public datasets.Report a data error.